MedTrace Logo

A Randomized Controlled Trial to Investigate The Role of Adjuvant Inhalable Sodium Bicarbonate Solution 8.4% in Treatment of COVID-19

NCT05035524 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 340

Last updated 2021-09-05

No results posted yet for this study

Summary

The aim of the study is to investigate the role of SB 8.4% as adjuvant therapy in the treatment of COVID- 19 patients proved to be RT-PCR positive (mild, moderate and severe).

Conditions

Interventions

DRUG

Sodium Bicarbonate Solution

Inhalation of SB 8.4% via a jet nebulizer (5 ml every 4 h) starting at 7:00 to 23:00 hours every day for 30 days together with instillation of SB 8.4% drops 4-times daily (three drops for each nostril) were offered to all patients in the study group (El-Badrawy et al., 2019).

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Principal Investigators

  • Tamer El-Hadidy · Mansoura University Hospital - Chest Departement

  • Rehab Ahmad Elmorsey · Mansoura University Hospital - Chest Departement

  • Ibrahim Badr · Mansoura University Hospital - Chest Departement

  • Mohammed shehta · Mansoura University Hospital - Chest Departement

  • Adel El-Badrawy · Mansoura University Hospital - Chest Departement

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2022-03-01
Completion
2022-03-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05035524 on ClinicalTrials.gov